Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANXENE vs GEN-XENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.
Benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.
Anxiety disorders,Short-term relief of anxiety symptoms,Alcohol withdrawal syndrome,Adjunctive treatment for partial seizures
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation (off-label),Alcohol withdrawal (off-label)
7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.
Initial: 10 mg PO TID; maintenance: 20-40 mg/day PO in divided doses; max: 120 mg/day.
Terminal elimination half-life of the active metabolite desmethyldiazepam is 30-200 hours (mean ~100 hours); parent drug clorazepate is rapidly hydrolyzed and has negligible half-life. Accumulation occurs with repeated dosing, leading to delayed peak effects and prolonged sedation.
30–100 hours (mean ~50 h); prolonged in elderly and hepatic impairment; steady-state achieved in 7–10 days.
Hepatic via oxidative metabolism; primarily by CYP3A4 and CYP2C19 to active metabolite nordazepam, then to oxazepam and others. Also undergoes glucuronidation.
Hepatic via CYP3A4; active metabolite N-desmethyldiazepam; also undergoes glucuronidation.
Primarily renal (80-90% as conjugated metabolites, including oxazepam and desmethyldiazepam); biliary/fecal excretion accounts for <10%.
Renal: ~80% as glucuronide and oxidized metabolites; fecal: ~20% via biliary excretion.
Clorazepate and desmethyldiazepam: 95-98% bound to albumin.
95–99% bound, primarily to albumin.
Clorazepate: 0.2-0.3 L/kg. Desmethyldiazepam: 0.5-1.5 L/kg (large Vd indicates extensive tissue distribution).
0.5–2.0 L/kg; indicates extensive tissue distribution.
Oral: nearly 100% (prodrug completely hydrolyzed in gastric acid to desmethyldiazepam). Intramuscular: erratic and incomplete (approximately 50-70% bioavailability due to variable absorption).
Oral: 85–100%; rectal: 90%.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50% and use with caution.
Cr Cl 30-60 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: use not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Children 9-12 years: 7.5 mg orally twice daily; increase to 7.5 mg three times daily if needed. Not recommended under 9 years.
Not recommended for use in children under 6 years; for children ≥6 years: initial 5 mg PO BID, titrate as needed up to 60 mg/day.
Initiate at 3.75 mg orally 1 to 2 times daily; titrate slowly to avoid sedation and falls.
Initial: 5 mg PO BID; increase slowly; max: 60 mg/day; increased sensitivity to CNS effects.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate alternative treatment options.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Risk of dependence and withdrawal seizures with abrupt discontinuation,CNS depressant effects may impair driving or operating machinery,Use caution in hepatic impairment,Avoid in pregnancy (risk of neonatal withdrawal and floppy infant syndrome),Potential for anterograde amnesia,Elderly patients at increased risk for adverse effects
Risk of dependence and withdrawal reactions after prolonged use,CNS depressant effects may impair mental alertness,Use with caution in elderly and debilitated patients due to increased sensitivity and fall risk,May cause anterograde amnesia,Should not be abruptly discontinued after long-term use
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe hepatic impairment,Pregnancy (especially first trimester),Breastfeeding,Concomitant use with opioids unless alternative treatments are inadequate
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Pre-existing CNS depression,Severe hepatic impairment,Pregnancy (especially first trimester)
No specific food interactions. Grapefruit juice does not significantly affect metabolism. Fatty meals may delay absorption of oral clorazepate, but overall bioavailability not affected.
No significant food interactions are documented. Take with or without food. Grapefruit juice does not affect metabolism (clorazepate is not CYP3A4 dependent).
FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to physical dependence and withdrawal symptoms in the neonate, including floppy infant syndrome, respiratory depression, and feeding difficulties. Late pregnancy or near delivery: Risk of neonatal sedation, hypotonia, and withdrawal.
First trimester: Increased risk of congenital malformations (e.g., oral clefts) with exposure. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depression (floppy infant syndrome), and withdrawal symptoms in neonates. Late third trimester or delivery: Potential for neonatal withdrawal syndrome.
Excreted in human milk. M/P ratio not established. Case reports indicate low milk levels (approx 4-10% of maternal weight-adjusted dose) but infant accumulation possible due to long half-life. Benefits of breastfeeding should be weighed against potential risks of sedation and poor feeding in the infant. Monitor infant for drowsiness, poor suckling, and weight loss.
Excreted into breast milk; M/P ratio approximately 0.1-0.5. Avoid breastfeeding due to risk of infant sedation, poor feeding, and potential accumulation. Consider alternative agents.
Due to increased volume of distribution and enhanced clearance, higher doses may be required during pregnancy to maintain efficacy, especially in the second and third trimesters. However, dose adjustment should be individualized and cautious because of potential fetal risks. Use the lowest effective dose for the shortest duration. Avoid high doses near term.
Increased clearance and volume of distribution during pregnancy may require dose escalation. Monitor clinical response and adjust as needed; avoid during first trimester if possible and use lowest effective dose in later trimesters.
TRANXENE (clorazepate) is a benzodiazepine prodrug that is decarboxylated in the stomach to the active metabolite N-desmethyldiazepam. Onset of action is relatively slow (1-2 hours) compared to diazepam. Due to its long half-life (up to 100 hours for active metabolite), accumulation is possible in elderly or hepatically impaired patients. Avoid in narrow-angle glaucoma. Abrupt discontinuation may precipitate withdrawal seizures.
Gen-Xene (clorazepate dipotassium) is a benzodiazepine pro-drug that is rapidly decarboxylated to nordiazepam in the stomach. This leads to a slow onset but long duration, making it useful for anxiety with once-daily dosing. Due to active metabolites (nordiazepam, oxazepam), accumulation can occur in elderly or hepatic impairment. Avoid in acute narrow-angle glaucoma. Taper gradually to prevent withdrawal.
Do not stop taking suddenly; taper under medical supervision to avoid withdrawal symptoms.,Avoid alcohol and other CNS depressants (e.g., opioids, sleep aids) as they increase sedation and respiratory depression risk.,May cause drowsiness, dizziness; avoid driving or operating machinery until effect is known.,Take with or without food. Do not crush or chew extended-release capsules.,Inform doctor if you have a history of substance abuse, liver disease, or glaucoma.,Use caution in elderly patients due to increased risk of falls and cognitive impairment.,Notify doctor immediately if you experience suicidal thoughts, unusual mood changes, or allergic reactions.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol and other CNS depressants while taking this medication.,Drowsiness or dizziness may occur; avoid driving until you know how you react.,Do not stop abruptly; withdrawal symptoms (anxiety, insomnia, seizures) can occur.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANXENE vs GEN-XENE, answered by our medical review team.
TRANXENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine; enhances GABA-A receptor activity by binding to benzodiazepine site, increasing chloride ion influx and neuronal hyperpolarization.. GEN-XENE is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANXENE and GEN-XENE depend on the specific clinical indication. These are both Benzodiazepine Anxiolytic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANXENE is: 7.5 mg to 15 mg orally 2 to 4 times daily; maximum dose 90 mg/day.. The standard adult dose of GEN-XENE is: Initial: 10 mg PO TID; maintenance: 20-40 mg/day PO in divided doses; max: 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANXENE and GEN-XENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANXENE is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip/palate, when used during the first trimester. Second and third trimest. GEN-XENE is classified as Category C. First trimester: Increased risk of congenital malformations (e.g., oral clefts) with exposure. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depressio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.